Related Experiment Videos
"Timolol in essential hypertension" a preliminary report
Insights
Timolol, a new beta-adrenergic blocking drug, effectively lowers blood pressure in patients with essential hypertension. Most patients experienced satisfactory results, with bradycardia being the main side effect observed.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential hypertension is a widespread condition requiring effective treatment.
- Beta-adrenergic blocking agents are a key class of antihypertensive medications.
Purpose of the Study:
- To evaluate the efficacy and safety of Timolol (Blocadren) in treating essential hypertension.
Main Methods:
- A clinical trial involving twelve previously untreated patients with essential hypertension.
- Administration of Timolol twice daily.
Main Results:
- A significant reduction in systolic and diastolic blood pressure was observed in eleven out of twelve patients.
- One patient was withdrawn due to excessive bradycardia.
- No other serious adverse effects were reported.
Conclusions:
- Timolol demonstrates promising efficacy in managing essential hypertension.
- Further long-term studies are recommended to establish Timolol's role in antihypertensive therapy.
Abstract:
A study of a new beta-adrenergic blocking drug TIMOLOL (Blocadren) in the treatment of essential hypertension has been undertaken. Twelve hypertensive patients previously undiagnosed and untreated were studied. Results with a twice a day dose of the drug showed a satisfactory fall in systolic and diastolic pressures in all but one patient, who was withdrawn from the trial because of excessive bradycardia. Apart from bradycardia, no serious side effects were observed in the patients. Observation over longer period is advocated to determine the place of Timolol in our antihypertensive armamentorium.